Literature DB >> 2424363

The pharmacology and toxicology of the interferons: an overview.

G J Mannering, L B Deloria.   

Abstract

Interferon was discovered three decades ago. The next 20 or more years of research were directed largely toward an understanding of its antiviral activity. The persistent short supply of interferon hampered progress, and the impure preparations available throughout these years clouded interpretation of results. Many of the experiments and clinical studies that interferonologists had dreamed of for 20 or more years became realities when modern technology provided quantities of pure interferon that exceeded expectations. Studies with these pure recombinant interferons removed all doubts that the many pleiotropic effects that had been observed with impure interferon preparations were due to interferon and not to the impurities. The interferons are now acknowledged lymphokines that are involved in many cellular processes. In fact, the antiviral activity of interferon, which led to its discovery, may be an exaggerated adaptive utilization of an interferon-regulated function that plays a more general role in cellular physiology. The ability to isolate, purify, and produce pure interferon has led to the discovery of multiple species of leukocyte interferon. These interferons display different patterns of activity when tested by a variety of systems. This suggests that specific leukocyte interferons may be involved in specific physiological functions. Results of preliminary trials of the interferons as antiviral and antitumor agents have been encouraging and occasionally dramatic. The overall clinical picture is expected to improve when more is learned about the pharmacokinetics of the interferons and which of the interferons are best suited for the treatment of specific tumors and antiviral diseases. There are indications that coadministration of interferons with chemical antineoplastic and antiviral agents may increase the effectiveness of interferon in clinical situations. As might be expected of agents that influence a large number of physiological functions, interferons produce numerous toxic side effects, some of which resemble those inflicted by viral diseases. These side effects are reversible and not life threatening.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2424363     DOI: 10.1146/annurev.pa.26.040186.002323

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  18 in total

1.  Pharmacokinetics of recombinant interferon alpha-C.

Authors:  O Merimsky; M Rubinstein; D Fischer; A Danon; S Chaitchik
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Effect of interferon-alpha on DOI-induced wet-dog shakes in rats.

Authors:  A Kugaya; A Kagaya; Y Uchitomi; N Yokota; S Yamawaki
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 3.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

4.  Interferon-alpha/beta inhibits IgE-dependent histamine release from rat mast cells.

Authors:  M Swieter; W A Ghali; C Rimmer; D Befus
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

5.  Effect of the immunomodulator tilorone on the in vivo acetylation of procainamide in the rat.

Authors:  C K Svensson; P W Knowlton
Journal:  Pharm Res       Date:  1989-06       Impact factor: 4.200

6.  Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells.

Authors:  P K Peterson; B Sharp; G Gekker; C Brummitt; W F Keane
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

7.  Brain metastases of malignant melanoma in interferon complete responders: clinical and radiological observations.

Authors:  O Merimsky; M Inbar; I Reider-Groswasser; S Chaitchik
Journal:  J Neurooncol       Date:  1992-02       Impact factor: 4.130

8.  Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants.

Authors:  O G Khatsenko; S S Gross; A B Rifkind; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

Review 9.  Associations between physical activity and susceptibility to cancer: possible mechanisms.

Authors:  R J Shephard; P N Shek
Journal:  Sports Med       Date:  1998-11       Impact factor: 11.136

10.  Brain metastases of metastatic malignant melanoma: response to DTIC and interferon-gamma.

Authors:  D Schadendorf; M Worm; B M Czarnetzki
Journal:  J Neurooncol       Date:  1993-04       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.